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Abstract. The epidemiology of Hodgkin lymphoma (HL) has always been a source of fascination to 
researchers due to its heterogeneous characteristics of presentation. HL is an uncommon neoplasm 
of B-cell origin with an incidence that varies significantly by age, sex, ethnicity, geographic location 
and socioeconomic status. This complex pattern was also found to be replicated among 
Mediterranean basin populations. HL incidence rates progressively decreased from industrialized 
European countries such as France (ASR=2.61) and Italy (ASR=2.39) to less developed nations such 
as Albania (ASR=1.34) and Bosnia Herzegovina (ASR=1.1). Regarding HL mortality we have found 
that countries with the lowest incidence rates show the highest number of deaths from this cancer 
and viceversa. Finally, a wide gap in terms of survival was showed across the Mediterranean basin 
with survival rates ranged from 82.3% and 85.1% among Italian men and women, to 53.3 % and 
59.3% among Libyan men and women, respectively. Factors such as the degree of socio-economic 
development, the exposure to risk factors westernization-related, the availability of diagnostic 
practices along with different genetic susceptibilities to HL may explain its variation across 
Mediterranean countries. Furthermore, the lack of health resources decisively contribute to the 
poor prognosis recorded in less developed region. In the future, the introduction of appropriate and 
accessible treatment facilities along with an adequate number of clinical specialists in the treatment 
of HL and other cancers are warranted in order to improve the outcomes of affected patients and 
treat a largely curable type of cancer in disadvantaged regions.  
Introduction. Hodgkin lymphoma (HL) is a lymphoid 
malignancy of B-cell origin which is classified into 
either nodular lymphocyte predominant Hodgkin 
lymphoma (NLPHL) or classical Hodgkin lymphoma 
(CHL) in accordance with 2008 WHO classification. 
Although they have characteristics in common, these 
two disease entities differ in their clinical features and 
behavior as well their cellular properties i.e. 
morphology, immunophenotype and the preservation 
or extinction of the B-cell gene expression program. 
CHL accounts for 95% of all HLs and can be further 
subdivided into four histological subtypes: 
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lymphocyte-rich (LR), nodular sclerosis (NS), mixed 
cellularity (MC) or lymphocyte-depleted (LD).¹ HL is 
an uncommon neoplasm with an incidence that varies 
significantly by age, sex, ethnicity, geographic location 
and socioeconomic status.  
Incidence rates are higher in more developed 
regions and among males and lower in Asia. In the 
United States, about 9,290 new HL cases are estimated 
for 2013, an incidence of 2.8 per 100,000 people per 
year.² 
The hallmark of HL epidemiology is its variation in 
occurrence by age at diagnosis. This is represented in 
industrialized countries by the well-known bimodal 
curve showing two peaks: the most significant for 
young-adults (15-34 years of age) and the second one 
occurring in later life (above the age of 50). As already 
reported by Cozen et al, these peaks are composed 
mainly of different subtypes with the NS pathology 
being predominantly represented in the earlier age peak 
and the MC disease being predominant in the later age 
peak.³  
Despite its relatively low incidence and its low 
lifetime risk, HL accounts for 15% of all cancers in 
young adults with a high impact on quality of life. 
Since its earliest description in the first half of the 19
th
 
century, HL has proved to be a difficult form of 
neoplasm to understand because of its unusual 
histopathological aspects i.e. its resemblance to an 
infectious process, the variability of B-cell antigen 
expression among its subtypes and its occurrence in 
childhood and young adults. The etiology and 
pathogenesis of HL thus remain poorly understood.  
Epidemiological studies of HL to date have 
elucidated only some aspects of this heterogeneous 
disorder. Future studies of wider populations are thus 
necessary to more fully clarify the complexity of HL. 
In this review, we provide a comprehensive description 
of the known epidemiological features of HL, focusing 
on populations in the Mediterranean basin, and discuss 
the geographic, ethnic, socio-demographic and 
economic factors that impinge upon these properties. 
Regional comparisons of patterns and trends for HL 
between and within countries were also performed in 
support our meta-analysis. 
 
Materials and Methods. For the purposes of this 
study, we defined the Mediterranean area as the region 
incorporating countries around the Mediterranean Sea 
in Europe, Asia and Africa. We thus collated 
epidemiologic data on HL from Spain, France, Italy, 
Croatia, Bosnia Herzegovina, Albania, Greece, Turkey, 
Syria, Lebanon, Israel, Cyprus, Egypt, Libya, Tunisia, 
Algeria, and Morocco (specifically the Maghreb region 
in Northwestern Africa). We derived the most recent 
estimates on HL incidence and mortality from the 
updated International Agency for Research on Cancer 
(IARC) online database, GLOBOCAN 2012.⁴ 
Furthermore, more accurate statistics from the latest 
volume of Cancer Incidence in five continents (CI5, X 
version) were used to improve the quality of these 
data.5 Additional information was obtained from 
various local cancer registry reports available. 
Data regarding HL mortality and time trends for the 
specified Mediterranean countries were derived from 
the World Health Organization (WHO) mortality 
database online⁶. Most of the countries included in our 
analysis have previously published relevant data on HL 
epidemiology, though the level of coverage, accuracy 
and updating varies considerably both within and 
between countries. For this reason, temporal trends for 
HL incidence, mortality and survival are reported only 
for those countries in which the collection activity of 
cancer registries covered a sufficiently wide period.  
Hereafter, we refer to classical HL in this report. 
 
Etiologic Epidemiology. 
Role of Epstein-Barr virus (EBV) and other viruses. 
Based on either epidemiological findings (e.g. bimodal 
age-incidence curve, social-class risk factors, role of 
protected childhood environment) or clinical features 
(e.g. fever, night sweat, weight loss, elevated 
erythrocyte sedimentation rate or IL-6 in serum) it has 
long been hypothesized a viral etiology for HL.
7-8
 The 
ubiquitous B-lymphotropic oncogenic Herpesvirus, 
EBV, has been proposed as the major candidate for a 
pathogenetic role due to at least three pieces of 
evidence: the biological plausibility of EBV-mediated 
B cell transformation, the presence of clonal EBV 
genomes within HL tumor cells and three-fold elevated 
risk of HL in persons with a history of infectious 
mononucleosis.
9-11
  
Globally, EBV-positive HLs account for up to 40% 
of all HL cases, and they have been shown to vary 
substantially by patient demographic and tumors 
characteristics. The presence of EBV in HL is strongly 
associated with specific epidemiological features 
including male gender, Hispanic ethnicity, mixed 
cellularity subtype, children and older adults, lower 
socio-economic status. 
The rate of EBV-positive among HLs differs 
markedly worldwide especially with respect to 
geography: in North America and Western Europe, 
EBV was detected in 30 to 50% of HL patients, while 
in some parts of Latin America, Africa and Asia the 
percentage is much higher, reaching roughly 100% in 
children.¹² For instance, in Peru and Mexico incidence 
of EBV positivity among HLs ranged from 50 to 95%, 
in China was 65% and in Kenya reached 92%.
13-17 
Previous mentioned clinicopathological features of 
EBV-associated HLs were also maintained across 
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Mediterranean countries, where the frequency of EBV-
positivity was 90% in Greece, 61.5% in Turkey, 50% 
in Egypt, 48% in Italy and 30% in Israel (even if 
Bedouin patients showed a 66.7% rate of EBV 
infection).
18-20
 
The scenario is quite different for EBV-negative 
cases, in which a delayed exposure to common 
childhood virus other than EBV, such as other 
Herpesviruses and Polyomaviruses, has been 
postulated having a causative role in the development 
of HL. However, to date, no consistent association 
between any virus and EBV-negative HLs have been 
described.  
Conditions characterized by immune dysregulation 
and an immunodeficiency status may cause a 
predisposition to the development of this malignancy. 
In addition, the main cause of immunodeficiency relies 
on HIV infection in developed as well in developing 
countries.²¹ As a result, the risk of developing HL in 
HIV patients was estimated at 11-18-fold higher than 
in the general population.²² Given the remarkable 2012 
estimated number of people newly infected with HIV 
of 32.000 and 29.000 in Western and Central Europe 
and Middle East and Northern Africa respectively, 
such infectious disease is like to continue to be 
responsible for a proportion of HL cases in this area.²³ 
 
Tubercolosis and Hodgkin lymphoma. Another 
interesting causative relationship is that existing 
between HL and tuberculosis (TBC). Nevertheless, 
apart from some case reports, the literature lacks 
epidemiologic studies aimed at investigating such 
association. 
Both diseases share a pathobiology closely related 
to the loss of immune-surveillance of the host and, at 
the same time, side effects of anti-lymphoma treatment 
include immunosuppression, a well-known 
predisposing factor for TBC. 
Consequently, the risk of TBC is generally higher in 
HL patients, especially across endemic areas for TBC 
infection, such as the African and the Asian continents. 
In such regions, TBC has been described to precede but 
also to be concomitant or subsequent to HL.
24-26
  
Additionally, in some cases, HL and TBC can show 
similarities in terms of clinical presentation and course, 
laboratory tests and imaging findings.
27
 
Thus, the opportunity to distinguish between these 
two disorders represent a diagnostic challenge in 
countries with high prevalence of TBC. 
 
Familial aggregation and Hodgkin lymphoma. Early 
reports from familial cases of HL provided initial 
evidence towards a possible genetic predisposition as 
well as a role of shared environmental risk factors in 
the pathogenesis of HL. Moreover, the variability of 
HL incidence across different races, with rates higher 
in Jews and lower in Asians, further support this thesis. 
HL risk was found to be nearly 100-times higher in 
identical than in fraternal twins
28
 and over time 
multiple case-control and cohort studies have reported 
a threefold to ninefold higher risk of disease in first-
degree relatives of HL patients.
29-30
 These findings 
have been recently confirmed by linkages of 
population-based cancer and family record registries, in 
which considered large sample size and are less 
vulnerable to biases with respect to previous studies. 
Among them, a large study using data from the 
Swedish Family-Cancer Database and the Danish 
Cancer Registry, found a significantly increased risk of 
HL in first-degree relatives of patients with HL in both 
populations, with relative risks of 3.47 (95% CI, 1.77– 
6.80) in Sweden and 2.55 (95% CI, 1.01– 6.45) in 
Denmark and a pooled estimate of 3.11 (95%CI, 1.82–
5.29).
31
 
The risk of familial HL presented a heterogeneity of 
effect since it has been shown to vary by age, sex and 
degree of familial relationship. The greatest risk was 
seen for siblings than for parents of HL probands, for 
families of probands under 40 years (RR=4.25), for 
male relatives of patients. In addition, an earlier onset 
for familial than non-familial cases was found.
32
 
Increasingly, recent genome-wide analyses of 
candidate susceptibility genes identified various HLA 
class II polymorphisms (i.e. DRB5-0101 allele, 
DRB1*1501-DQA1*0102-DQB1*0602 haplotype and 
TAP 1 allele) as well as polymorphisms of several 
cytokine genes (e.g. IL6, IL1R1, IL10, IL4R) which 
have been linked to risk of HL.
33-36
 Furthermore, a 
genome-wide linkage screen performed in 44 high risk 
HL families showed the strongest linkage finding on 
chromosome 4p near the marker D4S394.
37
 
In summary, these findings support a multifactorial 
disease model for the pathogenesis of HL involving 
both genetic and environmental risk factors.  
 
Descriptive epidemiology. 
HL incidence patterns and time trends. Based on its 
epidemiological features, including in Mediterranean 
countries, HL incidence rates are higher in southern 
Europe, with the exception of Israel and Lebanon. The 
highest incidence of HL was in fact recorded in Israel 
in 2012 with an estimated incidence age-standardized 
rate (ASR) of 3.71 per 100,000, followed by Lebanon 
(ASR=3.67), Croatia (ASR=3.09), France (ASR=2.61) 
and Italy (ASR=2.39). The lowest incidence was 
recorded in Albania with an ASR of 1.1 per 100,000. 
Other countries with a low HL incidence included 
Bosnia Herzegovina (ASR=1.34), Egypt (ASR=1.51), 
Morocco (ASR=1.7) and Algeria (ASR=1.83).4 These 
data are reported in more detail in Table 1.  
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Figure 1. Incidence age-standardized rates for HL across the Mediterranean basin. 
 
 
 
Table 1. HL incidence, mortality and prevalence in Mediterranean countries from the GLOBOCAN 2012 online database. 
Country Incidence ASR (M/F) Mortality (ASR) 5-year prevalence 
Israel 3.71 (3.87/3.58) 0.33 15.76 
Lebanon 3.67 (4.23/3.16) 1.56 15.39 
Croatia 3.09 (3.28/2.93) 0.31 14.98 
France 2.61 (2.51/2.74) 0.29 11.75 
Italy 2.39 (2.76/2.02) 0.37 10.37 
Spain 2.29 (2.44/2.16) 0.26 9.19 
Turkey 2.12 (2.84 /1.42) 1.06 7.94 
Greece 2.06 (2.20/1.93) 0.8 11.89 
Sirya 2.06 (2.25/1.88) 1.39 7.93 
Libya 1.94 (1.84/2.04) 0.81 9.55 
Cyprus 1.89 (2.08/1.70) 0.34 8.35 
Tunisia 1.88 (2.21/1.56) 0.89 7.24 
Algeria 1.83 (1.78/1.89) 1 7.24 
Morocco 1.7  (1.86/1.56) 1.16 5.7 
Egypt 1.51 (1.93/1.11) 0.93 5.23 
Bosnia Herzegovina 1.34 (1.12/1.57) 0.38 6.31 
Albania 1.1  (1.59/0.62) 0.46 5.57 
ASR, age-standardized rate. 
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GLOBOCAN 2012 estimates of HL incidence were 
found to be globally in line with the above population-
based data, although some interesting differences were 
observed. In this regard, we found consistent variation 
in the recorded HL incidence rates between Globocan 
and published cancer registries data in Israel, Cyprus, 
Croatia and also among Algerian men. Of particular 
note, the most updated incidence data from the Israel 
National Cancer Registry reported lower rates than 
GLOBOCAN 2012 i.e. ASRs of 3.14 and 3.21 reported 
in Jewish men and women, respectively, and an ASR 
of 2.62 reported for non-Jewish women differed from 
the GLOBOCAN estimates; the only comparable rate 
was for non-Jewish men (ASR=3.87).
38
 Estimates and 
population-based data from the more developed 
Mediterranean countries on HL were comparable to 
those of other industrialized regions worldwide, such 
as the United States which reports an incidence of 2.8 
per 100,000 men and women per year.² 
In Italy, the ASR for HL reported by Associazione 
Italiana Registro Tumori (AIRTUM) was 3.4 per 
100,000 in both sexes in 2008. More updated data have 
revealed a slight geographic gradient in HL incidence 
across the Italian peninsula from north to south but this 
was not a statistically significant variation. The 2006-
2009 European ASRs for HL by sex and geographic 
area were as follows: north (4.1), center (3.8) and 
south/islands (3.8) in men and north (3.3), center (3.5) 
and south/islands (2.8) in women.
39
 About time trends, 
the HL incidence rates remained relatively stable 
among industrialized countries, comparable to the 
recorded rates in the United States which changed 
minimally over time; a significant increase in HL rates 
has only been seen only among blacks (APC=1.0) and 
Asians/Pacific Islanders (APC=2.2) since 1992.² 
Recent epidemiologic analysis conducted in Spain has 
revealed no significant frequency variations in HL 
incidence between 2000 and 2009.
40
 Some exceptions 
have been found in other part of Europe however: 
statistically significant 2.6% and 2.2% annual 
percentage increases in the HL rates in Italy have been 
documented by the AIRTUM in men and women, 
respectively, during the 1996-2010 period.
41
  
About the incidence in other countries bordering the 
Mediterranean Sea in recent years, a population-based 
study from the Israel Cancer Registry reported a 
significant and persistent rise in the ASR in both sexes 
between 1960 and 2005 in the Jewish population. Of 
particular note, in Israeli-born young Jewish adults, the 
ASR rose from 2.27 per 100,000 during the 1960-1969 
period to 3.61 during the years 1997-2005.
42
 Thus far, 
no HL incidence trends have been available for low-
income countries in the Mediterranean basin. 
Mortality patterns and time trends. Mortality rates due 
to HL vary markedly across the Mediterranean region; 
the estimated 2012 mortality ASRs range from 0.26 per 
100,000 in Israel to 1.56 per 100,000 in Lebanon. A 
correlation between socio-economic status and death 
from HL has also emerged within this region. High 
income countries such as Spain, France, Israel and Italy 
showed mortality rates of 0.26, 0.29, 0.33, and 0.37 per 
100,000, respectively. On the other hand, higher 
mortality rates have been recorded in Lebanon 
(ASR=1.56), Syria (ASR=1.39), Morocco (ASR=1.16) 
and Turkey (ASR=1.06).
4
 Data on HL mortality in 
Mediterranean regions are summarized in more detail 
in Table 1.  
Over the past 40 years, trends in mortality have 
progressively decreased worldwide, though they have 
been variable across countries. Since the late 1950s, 
mortality rates have steadily declined in industrialized 
countries. ASRs have plummeted from 2.27 to 0.44 in 
men and from 1.40 to 0.29 in women in Italy, from 
1.47 to 0.37 in men and from 0.88 to 0.24 in women in 
France and from 1.04 to 0.41 in men and from 0.55 to 
0.22 in women in Spain. In Italy, the same progressive 
downward trend has also been reported by AIRTUM 
which has recorded a drop in mortality rates for HL 
from 0.77 and 0.48 in 1992 to 0.40 and 0.27 in 2007 in 
men and women, respectively.
39
 In contrast to the 
above data, no similar trends seem to have emerged 
from low-income countries: the only available 
mortality time trends in this regard are from Egypt and 
show no change over time. 
Survival patterns and time trends. Up to the 1960s, the 
5-year survival rate for HL was less than 10% 
worldwide.
43
 The outcome for patients diagnosed with 
HL has progressively improved since then and the 
majority of cancer registries around the world report 
current 5-year overall survival (OS) rates of up to 80% 
for patients with advanced and more than 90% for 
limited stage disease. Hence, HL may be currently 
considered to be one of the most curable cancers 
worldwide.  
Overall, the highest survival rates for HL patients 
have been recorded in western countries. In southern 
Europe the 5-year relative survival (RS) rates are 
comparable to those of the United States and other 
European countries. An international geographic 
comparison performed by AIRTUM in 2011 has 
reported 5-RS rates for men of 82.3% in Italy, as 
compared to 79.1% in the United States (SEER-17) and 
82.5% in some European countries (EUROCARE-4); 
among females, these rates were slightly higher (85.1, 
83.7% and 84%, respectively).
41
 In recent years, a 
Europe-wide study analyzing the survival of patients 
with lymphoid neoplasms has indicated a 5-year RS of 
84.5% for HL patients diagnosed from 2000-2002. 
These rates were highest for patients with LR (5-year 
RS, 93.1%) and lowest for LDC cases (5-year RS, 
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54.4%). No statistically significant differences were 
found for CHL between men and women (82.5% vs. 
86%). That study also suggested that previously noted 
differences in HL survival rates between regions have 
tended to decrease, ranging from 81.4% in eastern 
Europe to 90.6% in northern Europe.
44
 Moreover, in 
this study, the outcome for patients with all lymphoid 
neoplasms, including HL, was reported to decrease 
substantially with age, as has been well documented for 
most types of cancer. Nevertheless, a large population-
based study from Sweden incorporating the results of 
long-term follow-ups has recorded a significant 5-year 
and 10-year RS improvement in all age categories, 
including the elderly but with the exception of the very 
old (> 80 years).
45
 Furthermore, a relevant increase in 
survival for HL patients aged 45 to 59 years, and 60 
years and older, was recently documented in a study 
from the United States (increases in the 10-year RS by 
24.8% and 23.3% between 1980-84 and 2000-04, 
respectively).
46
  
In contrast, the scenario is quite different in more 
economically disadvantaged Mediterranean regions. 
For example, the Libyan Benghazi Cancer Registry has 
reported a 5-year overall survival (OS) for HL patients 
of only 53.3 % in men and 59.3% in women during the 
period 2003-2005.
47
 Turkey has reported rates that 
halfway between this and the outcomes in developed 
nations i.e. a 5-year RS of 69% for all ages and both 
sexes combined.
48
 A comparison of outcomes among 
three groupings of Mediterranean nations is provided in 
Table 2. 
 
Discussion. The epidemiology of HL has always been 
of interest to cancer researchers because of its 
heterogeneous patterns of presentation, and several 
etiopathogenetic theories have emerged over time. This 
complex pattern was also found to be replicated among 
Mediterranean basin populations, and several factors 
have been shown to exert their influence on this 
phenomenon. Although data regarding HL incidence, 
mortality, survival and time trends across this region 
are available mainly for European countries and are 
sparse or absent for the majority of other countries 
bordering the Mediterranean sea, we have highlighted 
below several points of discussion for incidence time 
trends in less developed nations. 
First, it emerged from our current investigation that 
there is a substantial variation in HL occurrence by 
geographic area: HL incidence rates progressively 
decreased from industrialized European countries such 
as France and Italy to less developed nations such as 
Albania and Bosnia Herzegovina. This is clearly 
consistent with the earliest findings of Correa and 
O'Connor, who first described the positive correlation 
between degree of socio-economic development and 
risk of HL.
49
 There is a remarkable differences in the 
global occurrence of HL, with incidence rates higher in 
southern Europe than in northern Africa and western 
Asia. That seem to be largely due to a higher exposure 
in southern Europe to lifestyle and environmental risk 
factors associated with economic transition (including 
smoking, obesity, physical inactivity, and reproductive 
behaviors), as well as availability of diagnostic 
practices and awareness of disease. In fact, although 
little is currently known about HL pathogenesis, there 
is accumulating evidence that the adoption of western 
world-associated risk factors by low income countries, 
the so-called westernization, is responsible for 
increasing the number of HL cases in such areas.
50
 
A recent analysis performed by InterLymph has 
found that cigarette smoking should be added to the 
few modifiable HL risk factors identified to date, with 
a reported odds ratio (OR) of 1.10 in ever smokers 
compared to never smokers. This increased risk was 
also associated with MC (OR=1.60) and EBV-positive 
CHL (OR=1.80) among current smokers.
51
  
On the other hand, different genetic susceptibilities 
to HL between different races may play an important 
role in explaining its variation across countries. As 
already reported, Asians have a lower incidence of HL 
than Caucasians and Blacks, which may indicate a 
genetic resistance to this disease that is possibly related 
to HLA type.
52
 Nevertheless, in Israel, which belongs 
to western Asia, the HL rates were found to be the 
highest of the Mediterranean region. In particular, 
Israeli Jews had incidence rates of 4.17 and 5.57 in 
men and women, respectively, aged between 15 and 34 
years. These rates were lower among Israeli non-Jews 
with ASRs of 3.02 in males and 1.57 in females aged 
15-34. These findings may suggest an influence of 
genetic background on HL incidence, but 
environmental influence must also be taken into
Table 2. HL survival rates for selected countries in three Mediterranean macroareas 
Mediterranean Area Country 
5 yr survival 
male female 
Southern Europe Italy 75% 89% 
Southern Europe France 83% 
Southern Europe Spain 86.4% 
Northern Africa Libya 53.3% 59.3% 
Western Asia Turkey 69% 
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account. In fact, Israeli Jews born in America and 
Europe have shown the highest HL rates (4.16 and 6.51 
in men and women, respectively) at an equivalent 
age.
53
 Moreover, Au et al. have previously 
corroborated the role of both genetic and 
environmental factors in the occurrence of HL: Chinese 
immigrants in British Columbia presented a 
significantly lower 25-year incidence for HL compared 
to the rest of the population in this region (standardized 
incidence ratio, SIR =0.34) but a still higher rate than 
would be expected for the Hong Kong Chinese 
population (SIR=2.81).
54
 
With regard to incidence trends, these have 
remained relatively stable over time in western 
countries but have been increasing in regions 
experiencing improved standards of living. This 
reported rise in HL rates in less developed countries 
since the mid-1990s55 may be explained by 
westernization,
50
 the aging and growth of the 
population, or the adoption of behaviors and lifestyles 
associated with economic development such as 
smoking, less healthy diets and physical inactivity.  
Over the coming decades, these factors will 
contribute to an increased overall burden of cancer, 
especially in low income countries, where HL is 
expected to rise among young adults by nearly 57% by 
2035. Keeping in mind all aspects of bias related to 
predictions, in the same year in the East Mediterranean 
region, the estimated number of new HL cases will rise 
from 8,374 to 13,110 per year. 
Among European countries, the increase in 
incidence will be less with the estimated number of 
new cases expected to rise from 20,410 to 21,076 
annually in both sexes by 2035, with 76% (16,010) of 
these patients aged below 65 years. 
In southern Europe as well as in the United States, 
no consistent patterns have been shown to date, with 
stable or slightly downward trends recorded in men and 
less favorable rates in women, reflecting the absence of 
any new identified causes of HL over the last few 
decades.
56
 The only exception to this trend in southern 
Europe has been in Italy, where a significant annual 
increase in HL rates by 2.6% in men and 2.2% in 
women has been reported over the period from 1996 to 
2010. This increase seems not to have been due to new 
risk factors in the Italian population, as evidenced by 
the temporal stability of HL incidence seen in 
neighboring countries (i.e. France and Spain).
57
 A 
greater attention to diagnostic procedures may in fact 
explain this trend.  
The pronounced and isolated increase in the HL 
incidence in western Asia among Israeli-born young 
Jewish adults from 1960 to 2005 is currently a subject 
of investigation in which it has been hypothesized that 
as yet identified factors are responsible. Regarding HL 
mortality, as expected, we have found that countries 
with the lowest incidence rates show the highest 
number of deaths from this cancer and vice versa. The 
past few decades have been characterized by a 
significant progress in the management of HL and the 
introduction of more effective and less toxic front-line 
treatments within risk-adapted strategies have made 
this a largely curable disease. In most western and 
northern European countries, HL mortality has 
continued to steadily decline since the late 1960s. 
However, in central and eastern European countries 
this decrease has been relatively recent and in fact up 
to the 1990s central and eastern countries were 
characterized by unfavorable trends.
58
 Nevertheless, 
the clinical outcomes for HL patients have been 
variable across the Mediterranean basin. By comparing 
survival rates, we have found a particularly poor 
prognosis for HL patients in northern Africa, where the 
rates for HL are similar to those reported for non-
Hodgkin lymphoma in more developed countries (5-
year RS=57%).  
As reported by several authors, morphology 
strongly influences the prognosis of HL patients. In 
particular MC, LD and not otherwise specified (NOS) 
subtypes had significantly poorer outcome compared 
with NS or NLPHL.
59
 At the same time, HL subtype 
distributions seem to vary across the Mediterranean 
basin. For example, MC and NOS are more frequent in 
Algeria, Egypt, Libya and Turkey where mortality rates 
are among the highest in this area (Table 3). 
Unfortunately, no histological data are available from 
Lebanon, Syria or Morocco, where the estimated HL 
mortality ASR peaks at 1.56, 1.39 and 1.16, 
respectively (Table 1). However, differences in 
morphology explain only some of the geographic 
variations observed in survival outcome. A study 
coordinated by Ben Lakhal has suggested the presence 
of an intrinsically more aggressive HL affecting less 
developed countries including Tunisia,
60
 but further 
evidence is needed to confirm this finding. More 
importantly, a wide disparity in the availability of 
health resources may better explain the difference in 
HL mortality recorded within the Mediterranean basin. 
Radiotherapy represents an important resource for 
treating HL patients, particularly for cases of limited 
stage disease, but its availability is still low among 
Mediterranean low- and middle-income countries. In 
the Maghreb area, only Egypt with 85% coverage and 
Morocco with 89% coverage can provide an acceptable 
level of radiotherapy treatment. Libya has an adequate 
number of machines but not all are utilized due to a 
lack of cancer clinicians. In Albania, the issue is 
insufficient maintenance support despite this country’s 
serious efforts to provide adequate cancer care services 
to its citizens. The annual maintenance bill for these
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Table 3. Number of cases, deaths and prevalent subtype for HL in selected countries. 
Country No. of cases 
Male               Female 
No. of deaths 
Male             Female 
Prevalent subtype 
Male        Female 
Italy 1092                     933 231                      181 NS                   NS 
Spain 877                       646 147                      111 NS                   NS 
France 690                       569 168                      142 NS                   NS 
Croatia 330                       326 20                          13 NOS              NOS 
Egypt 226                       116 5                              2 MC                 MC 
Israel 599                       577 16                          13 NS                   NS 
Greece -                             - 133                        99 -                        - 
Albania -                             - 13                           2 -                        - 
Morocco 23                          15 -                            - -                        - 
Tunisia 154                       115 -                            - NS                   NS 
Libya 38                          44 -                            - NOS               MC 
Algeria 97                          63 -                            - NOS              NOS 
Turkey 336                       225 -                            - MC                  NS 
Cyprus 72                          61 -                            - NS                   NS 
Number of cases and prevalent subtype were modified from Cancer Incidence in 5 Continents volume X (2003-2007); 
Year of recorded mortalities: Italy (2010), Spain (2011), France (2009), Croatia (2011), Egypt (2011), Israel (2010), Greece (2010) and 
Albania (2004). 
MV, microscopically verified; NS, nodular sclerosis; NOS, not otherwise specified; MC, mixed cellularity  
 
machines of US$110,000 and requirement to replace 
one in three machines at a cost of US$150,000 is 
beyond the budget of the Albanian health system. In 
Syria the situation is not much better with only 2 
radiotherapy centers operating at present serving 22.4 
million people.
61
  
In addition, the ever increasing costs of new and 
innovative therapies may also contribute to the gap in 
survival outcomes that exist within the Mediterranean 
region. 
In conclusion, the provision of appropriate and 
accessible treatment facilities along with an adequate 
number of clinical specialists in the treatment of HL 
and other cancers represents a future challenge that 
must be overcome to improve the outcomes of affected 
patients and treat a largely curable type of cancer in 
disadvantaged regions. 
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